Cleared Traditional

CARESIDE APTT (K014028) - FDA 510(k) Clearance

Class II Hematology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K014028 · Careside Hemotology, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2002
Decision
64d
Days
Class 2
Risk

K014028 is an FDA 510(k) clearance for the CARESIDE APTT. Classified as Activated Partial Thromboplastin (product code GFO), Class II - Special Controls.

Submitted by Careside Hemotology, Inc. (Culver City, US). The FDA issued a Cleared decision on February 8, 2002 after a review of 64 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7925 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Careside Hemotology, Inc. devices

Submission Details

510(k) Number K014028 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 06, 2001
Decision Date February 08, 2002
Days to Decision 64 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
49d faster than avg
Panel avg: 113d · This submission: 64d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GFO Activated Partial Thromboplastin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7925
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GFO Activated Partial Thromboplastin

All 51
Devices cleared under the same product code (GFO) and FDA review panel - the closest regulatory comparables to K014028.
HemosIL Silica Clotting Time
K253957 · Instrumentation Laboratory (IL) Co. · Jan 2026
Cryocheck Hex LA
K193556 · Precision Biologic · Oct 2020
HemosIL Silica Clotting Time
K160445 · Instrumentation Laboratory CO · Mar 2016
HEMOSIL SYNTHASIL
K060688 · Instrumentation Laboratory CO · Apr 2006
HEMOSIL SILICA CLOTTING TIME
K050221 · Instrumentation Laboratory CO · Mar 2005
IL TEST APTT-SP
K973306 · Instrumentation Laboratory CO · Nov 1997